# NEW THERAPIES ASSESSMENT NEWS

## THE FINAL MOVE TO JOINT EU HTA ASSESSMENTS - ONCOLOGY

## CONTEXT

Oncology drugs including orphan oncology drugs will probably be the first subjects for joint EU clinical HTA. After three years, treatments in rare diseases outside cancer will be added, followed by all other drugs, and then medical devices two years later.

## DETAILS

The move will consider a 2-stepped approach: on the one hand, presentation of clinical evidence as a joint European scientific analysis of available data, and on the other hand, the freedom of member states in assessment of these data. The balance of interests must also be reflected in the details that have yet to be regulated, such as composition of the so-called "coordination group" that carries out the clinical assessment.

## CONCLUSIONS & POTENTIAL DIRECTION

Prepare for:

1. Supranational, joint assessment of clinical data across Europe for oncology treatments with/without orphan designation.
2. Value rating and price negotiations at national level.

The strategy to adopt will depend on the process and evaluation details to be developed. Also, length of the process will critically influence launch sequencing across European markets.

Source: Pressemitteilungen und Meldungen - Gemeinsamer Bundesausschuss (g-ba.de)

ASCENIAN HTA AND PAYER POLICY UPDATES | SEPTEMBER 2021




CONTACT:

MICHAEL.EPSTEIN@ASCENIAN-CONSULTING.COM